CA3266974A1 - ADDITIONAL DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) - Google Patents

ADDITIONAL DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA)

Info

Publication number
CA3266974A1
CA3266974A1 CA3266974A CA3266974A CA3266974A1 CA 3266974 A1 CA3266974 A1 CA 3266974A1 CA 3266974 A CA3266974 A CA 3266974A CA 3266974 A CA3266974 A CA 3266974A CA 3266974 A1 CA3266974 A1 CA 3266974A1
Authority
CA
Canada
Prior art keywords
hsct
tma
antibodies
administration
stem cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3266974A
Other languages
English (en)
French (fr)
Inventor
Stephan Ortiz
Jonathan MONTELEONE
Xiaofeng Wang REARS
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of CA3266974A1 publication Critical patent/CA3266974A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3266974A 2022-09-06 2023-09-01 ADDITIONAL DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) Pending CA3266974A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263404061P 2022-09-06 2022-09-06
US63/404,061 2022-09-06
US202363440984P 2023-01-25 2023-01-25
US63/440,984 2023-01-25
PCT/US2023/031836 WO2024054408A1 (en) 2022-09-06 2023-09-01 Supplemental dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)

Publications (1)

Publication Number Publication Date
CA3266974A1 true CA3266974A1 (en) 2024-03-14

Family

ID=88192212

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3266974A Pending CA3266974A1 (en) 2022-09-06 2023-09-01 ADDITIONAL DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA)

Country Status (9)

Country Link
EP (1) EP4583910A1 (enExample)
JP (1) JP2025529317A (enExample)
KR (1) KR20250060282A (enExample)
CN (1) CN120076827A (enExample)
AU (1) AU2023338677A1 (enExample)
CA (1) CA3266974A1 (enExample)
IL (1) IL319413A (enExample)
TW (1) TW202426048A (enExample)
WO (1) WO2024054408A1 (enExample)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
ES2796078T3 (es) * 2013-09-16 2020-11-25 Childrens Hospital Med Ct Composiciones y métodos para el tratamiento de la microangiopatía trombótica asociada al hsct
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
WO2016200627A1 (en) * 2015-06-09 2016-12-15 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
TW201718014A (zh) * 2015-10-12 2017-06-01 諾華公司 C5抑制劑於移植相關微血管病之用途
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
JP2023503776A (ja) * 2019-09-27 2023-02-01 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 造血幹細胞移植後の血栓性微小血管症（ｈｓｃｔ－ｔｍａ）の治療方法
JP7821160B2 (ja) 2020-08-13 2026-02-26 アレクシオン ファーマシューティカルズ， インコーポレイテッド 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与
CA3173016A1 (en) * 2021-01-22 2022-07-28 Gin-Fu CHEN Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody

Also Published As

Publication number Publication date
JP2025529317A (ja) 2025-09-04
TW202426048A (zh) 2024-07-01
WO2024054408A1 (en) 2024-03-14
AU2023338677A1 (en) 2025-03-27
IL319413A (en) 2025-05-01
EP4583910A1 (en) 2025-07-16
CN120076827A (zh) 2025-05-30
KR20250060282A (ko) 2025-05-07

Similar Documents

Publication Publication Date Title
IL300115A (en) Dosage and Administration of ANTI-C5 Antibodies for Hematopoietic Stem Cell Transplantation Treatment (HSCT-TMA)
ES2906725T3 (es) Vectores para el uso en un sistema de coexpresión inducible
SI4121007T1 (sl) Formulacije protiteles proti amiloidnemu beta peptidnemu protofibrilu z visoko koncentracijo in načini njihove uporabe
HK40088954A (en) Dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
IL319413A (en) Adjunctive dosing and administration of anti-C5 antibodies for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA).
IL319674A (en) Human anti-IL-1R3 antibody and methods of use
GB202417384D0 (en) Methods and systems for differentiation of cells using optogenetics
CA3261520A1 (en) ANTIBODIES, THEIR MANUFACTURING PROCESSES AND METHODS OF USE
IL304593A (en) Methods for the treatment of complement-mediated thrombotic microangiopathy using an anti-c5 antibody
WO2023010068A3 (en) Multiprotein-engineered cells secreting a multispecific antibody
EP4126961A4 (en) ANTI-CD6 ANTIBODY COMPOSITIONS AND METHODS FOR TREATING AND REDUCING NEGATIVE EFFECTS OF CORONAVIRUS WITH COVID-19
MX2022015740A (es) Dosificacion de anticuerpos neutralizantes de poliomavirus.
IL326085A (en) Methods for rapid manufacture of engineered t cells expressing chimeric antigen receptors
MX2025001954A (es) Anticuerpos agonistas de pd-1 y metodos para tratar enfermedades autoinmunes con un anticuerpo agonista de pd-1
WO2023192321A3 (en) Genetically engineered antibody resistant (gear) cells for adoptive cellular therapy
WO2023133296A3 (en) Engineered pd-l1-targeting gamma delta t cell receptors
CA3260770A1 (en) Bispecific anti-PCRV antibodies and blood products for the treatment of bronchiectasis
IL317698A (en) Methods and compositions for stem cell differentiation
MX2024003828A (es) Métodos de uso de anticuerpos antiesclerostina en el tratamiento de osteogénesis imperfecta.
GB202209676D0 (en) Methods and compositions for stem cell differentiation
WO2023034950A3 (en) Anti-hcmv antibodies and antigen-binding fragments thereof
WO2021247588A3 (en) Rabbit antibodies to human immunoglobulins g
GB202216387D0 (en) Solid oxide fuel cells and methods of operation
AU2024901504A0 (en) Enhanced chimeric antigen receptor t cell composition and method of use
CA3306361A1 (en) Tl1a associated antibody compositions and methods of use

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20250306

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250611

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250611

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250611

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250613

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20250613

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250820

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250903